Literature DB >> 18606820

Impaired regulation of brain mitochondria by extramitochondrial Ca2+ in transgenic Huntington disease rats.

Frank N Gellerich1, Zemfira Gizatullina, Huu P Nguyen, Sonata Trumbeckaite, Stefan Vielhaber, Enn Seppet, Stephan Zierz, Bernhard Landwehrmeyer, Olaf Riess, Stephan von Hörsten, Frank Striggow.   

Abstract

Huntington disease (HD) is characterized by polyglutamine expansions of huntingtin (htt), but the underlying pathomechanisms have remained unclear. We studied brain mitochondria of transgenic HD rats with 51 glutamine repeats (htt(51Q)), modeling the adult form of HD. Ca(free)(2+) up to 2 mum activated state 3 respiration of wild type mitochondria with glutamate/malate or pyruvate/malate as substrates. Ca(free)(2+) above 2 mum inhibited respiration via cyclosporin A-dependent permeability transition (PT). Ruthenium red, an inhibitor of the mitochondrial Ca(2+) uniporter, did not affect the Ca(2+)-dependent activation of respiration but reduced Ca(2+)-induced inhibition. Thus, Ca(2+) activation was mediated exclusively by extramitochondrial Ca(2+), whereas inhibition was promoted also by intramitochondrial Ca(2+). In contrast, htt(51Q) mitochondria showed a deficient state 3 respiration, a lower sensitivity to Ca(2+) activation, and a higher susceptibility to Ca(2+)-dependent inhibition. Furthermore htt(51Q) mitochondria exhibited a diminished membrane potential stability in response to Ca(2+), lower capacities and rates of Ca(2+) accumulation, and a decreased Ca(2+) threshold for PT in a substrate-independent but cyclosporin A-sensitive manner. Compared with wild type, Ca(2+)-induced inhibition of respiration of htt(51Q) mitochondria was less sensitive to ruthenium red, indicating the involvement of extramitochondrial Ca(2+). In conclusion, we demonstrate a novel mechanism of mitochondrial regulation by extramitochondrial Ca(2+). We suggest that specific regulatory Ca(2+) binding sites on the mitochondrial surface, e.g. the glutamate/aspartate carrier (aralar), mediate this regulation. Interactions between htt(51Q) and distinct targets such as aralar and/or the PT pore may underlie mitochondrial dysregulation leading to energetic depression, cell death, and tissue atrophy in HD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18606820      PMCID: PMC2662157          DOI: 10.1074/jbc.M709555200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

Review 1.  Bioenergetics at low oxygen: dependence of respiration and phosphorylation on oxygen and adenosine diphosphate supply.

Authors:  E Gnaiger
Journal:  Respir Physiol       Date:  2001-11-15

2.  Transgenic rat model of Huntington's disease.

Authors:  Stephan von Hörsten; Ina Schmitt; Huu Phuc Nguyen; Carsten Holzmann; Thorsten Schmidt; Thomas Walther; Michael Bader; Reinhard Pabst; Philipp Kobbe; Jana Krotova; Detlef Stiller; Ants Kask; Annika Vaarmann; Silvia Rathke-Hartlieb; Jörg B Schulz; Ute Grasshoff; Ingrid Bauer; Ana Maria Menezes Vieira-Saecker; Martin Paul; Lesley Jones; Katrin S Lindenberg; Bernhard Landwehrmeyer; Andreas Bauer; Xiao-Jiang Li; Olaf Riess
Journal:  Hum Mol Genet       Date:  2003-03-15       Impact factor: 6.150

3.  Limitations of cyclosporin A inhibition of the permeability transition in CNS mitochondria.

Authors:  N Brustovetsky; J M Dubinsky
Journal:  J Neurosci       Date:  2000-11-15       Impact factor: 6.167

Review 4.  Deranged neuronal calcium signaling and Huntington disease.

Authors:  Ilya Bezprozvanny; Michael R Hayden
Journal:  Biochem Biophys Res Commun       Date:  2004-10-01       Impact factor: 3.575

Review 5.  Energetic depression caused by mitochondrial dysfunction.

Authors:  Frank Norbert Gellerich; Sonata Trumbeckaite; Tobias Müller; Marcus Deschauer; Ying Chen; Zemfira Gizatullina; Stephan Zierz
Journal:  Mol Cell Biochem       Date:  2004 Jan-Feb       Impact factor: 3.396

6.  Permeability transition in rat liver mitochondria is modulated by the ATP-Mg/Pi carrier.

Authors:  Thilo Hagen; Christopher J Lagace; Josephine S Modica-Napolitano; June R Aprille
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2003-08       Impact factor: 4.052

Review 7.  The hunt for huntingtin function: interaction partners tell many different stories.

Authors:  Phoebe Harjes; Erich E Wanker
Journal:  Trends Biochem Sci       Date:  2003-08       Impact factor: 13.807

8.  In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease.

Authors:  Alexander V Panov; James R Burke; Warren J Strittmatter; J Timothy Greenamyre
Journal:  Arch Biochem Biophys       Date:  2003-02-01       Impact factor: 4.013

9.  Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.

Authors:  Alexander V Panov; Claire-Anne Gutekunst; Blair R Leavitt; Michael R Hayden; James R Burke; Warren J Strittmatter; J Timothy Greenamyre
Journal:  Nat Neurosci       Date:  2002-08       Impact factor: 24.884

10.  Characterization of superoxide-producing sites in isolated brain mitochondria.

Authors:  Alexei P Kudin; Nana Yaw-B Bimpong-Buta; Stefan Vielhaber; Christian E Elger; Wolfram S Kunz
Journal:  J Biol Chem       Date:  2003-11-18       Impact factor: 5.157

View more
  35 in total

Review 1.  The chicken or the egg: mitochondrial dysfunction as a cause or consequence of toxicity in Huntington's disease.

Authors:  Aris A Polyzos; Cynthia T McMurray
Journal:  Mech Ageing Dev       Date:  2016-09-12       Impact factor: 5.432

Review 2.  Mutant Huntingtin and Elusive Defects in Oxidative Metabolism and Mitochondrial Calcium Handling.

Authors:  Nickolay Brustovetsky
Journal:  Mol Neurobiol       Date:  2015-05-05       Impact factor: 5.590

3.  Mitochondrial membrane fluidity is consistently increased in different models of Huntington disease: restorative effects of olesoxime.

Authors:  Janett Eckmann; Laura E Clemens; Schamim H Eckert; Stephanie Hagl; Libo Yu-Taeger; Thierry Bordet; Rebecca M Pruss; Walter E Muller; Kristina Leuner; Huu P Nguyen; Gunter P Eckert
Journal:  Mol Neurobiol       Date:  2014-03-18       Impact factor: 5.590

4.  Homeostatic adaptations in brain energy metabolism in mouse models of Huntington disease.

Authors:  Ivan Tkac; Pierre-Gilles Henry; Lori Zacharoff; Michael Wedel; Wuming Gong; Dinesh K Deelchand; Tongbin Li; Janet M Dubinsky
Journal:  J Cereb Blood Flow Metab       Date:  2012-07-18       Impact factor: 6.200

5.  Oxidative metabolism and Ca2+ handling in striatal mitochondria from YAC128 mice, a model of Huntington's disease.

Authors:  James Hamilton; Tatiana Brustovetsky; Nickolay Brustovetsky
Journal:  Neurochem Int       Date:  2017-01-03       Impact factor: 3.921

6.  Exercise and metformin counteract altered mitochondrial function in the insulin-resistant brain.

Authors:  Gregory N Ruegsegger; Patrick M Vanderboom; Surendra Dasari; Katherine A Klaus; Parijat Kabiraj; Christina B McCarthy; Claudia F Lucchinetti; K Sreekumaran Nair
Journal:  JCI Insight       Date:  2019-09-19

7.  Oxygen Consumption Evaluation: An Important Indicator of Metabolic State, Cellular Function, and Cell Fate Along Neural Deregulation.

Authors:  Mariana Dutra Brito; Luiz Felipe Souza E Silva; Amanda Siena; Miruna Chipara; Sovan Sarkar; Tatiana Rosado Rosenstock
Journal:  Methods Mol Biol       Date:  2021

8.  Ca(2+) handling in isolated brain mitochondria and cultured neurons derived from the YAC128 mouse model of Huntington's disease.

Authors:  Jessica J Pellman; James Hamilton; Tatiana Brustovetsky; Nickolay Brustovetsky
Journal:  J Neurochem       Date:  2015-06-04       Impact factor: 5.372

Review 9.  Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease.

Authors:  Rodrigo A Quintanilla; Gail V W Johnson
Journal:  Brain Res Bull       Date:  2009-07-19       Impact factor: 4.077

Review 10.  Mitochondrial structural and functional dynamics in Huntington's disease.

Authors:  P Hemachandra Reddy; Peizhong Mao; Maria Manczak
Journal:  Brain Res Rev       Date:  2009-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.